EUVIMEDEUVIMED entdecken
Open Access

Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes

Lindsey Wang, Nora D Volkow, David C Kaelber, Rong Xu

JAMA Network Open · 11.08.2025 · 8 (8) · e2526327

DOI: 10.1001/jamanetworkopen.2025.26327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 11.08.2025. Verfasst von Lindsey Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Optic Neuropathy, Ischemic. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Semaglutide and tirzepatide, the new generation of glucagon-like peptide-1 receptor agonist used to treat type 2 diabetes and obesity, were recently reported to be associated with increased risk of nonarteritic anterior ischemic optic neuropathy (NAION). However, reported associations were inconsistent, and it remains unknown if semaglutide or tirzepatide is associated with other disorders of the optic nerve and visual pathways.

Objective

To examine associations of treatment with either semaglutide or tirzepatide with first-time diagnoses of optic nerve and visual pathway disorders in patients with type 2 diabetes. Design, Setting, and Participants This cohort study emulated target trials based on a nationwide, population-based database of US patient electronic health records from December 2017 to January 2023. Models were adjusted by propensity score matching. Eligible patients had type 2 diabetes and no prior diagnosis of eye disorders and were prescribed semaglutide, tirzepatide, or other antidiabetic medications. Exposures Prescription of semaglutide or tirzepatide vs other antidiabetic medications (insulins, metformin, dipeptidyl-peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, thiazolidinediones, and other glucagon-like peptide 1 receptor agonists). Main Outcomes and Measures First-time diagnoses of NAION and other optic nerve disorders during a 2-year follow-up were examined using Cox proportional hazards and Kaplan-Meier survival analyses.

Results

After propensity score matching among 1 511 637 eligible patients, the study population comprised 159 398 matched patients with type 2 diabetes (mean [SD] age, 56.5 [13.3] years; 83 123 women [52.15%]), including 79 699 patients in the semaglutide or tirzepatide group and 79 699 patients in the comparison group. During the 2-year follow-up, there were 35 patients (0.04%) with NAION in the semaglutide or tirzepatide group and 19 patients (0.02%) with NAION in the matched comparison group (hazard ratio, 1.76 [95% CI, 1.01-3.07]). There were 93 patients (0.12%) with other optic nerve disorders in the semaglutide or tirzepatide group and 54 patients (0.07%) with other optic nerve disorders in the matched comparison group (hazard ratio, 1.65 [95% CI, 1.18-2.31]). No association was found with other disorders of the optic nerve or visual pathways. Conclusions and Relevance In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of NAION and other optic nerve disorders, although the overall risk was low. These findings highlight the need for close monitoring of these conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsOptic Neuropathy, IschemicHumansFemaleMaleMiddle AgedAgedCohort StudiesGlucagon-Like Peptide-1 Receptor AgonistsTirzepatideGlucagon-Like Peptide 1Semaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsTirzepatideGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio.
  • National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, North Bethesda, Maryland.
  • Center for Clinical Informatics Research and Education, MetroHealth System, Cleveland, Ohio.
  • Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Wang, L., Volkow, N. D., Kaelber, D. C., & Xu, R. (2025). Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes. JAMA Network Open, 8(8), e2526327. https://doi.org/10.1001/jamanetworkopen.2025.26327

Vancouver

Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes. JAMA Network Open. 2025;8(8):e2526327. doi:10.1001/jamanetworkopen.2025.26327

BibTeX
@article{Wang2025,
  author = {Wang, Lindsey and Volkow, Nora D and Kaelber, David C and Xu, Rong},
  title = {Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {8},
  pages = {e2526327},
  doi = {10.1001/jamanetworkopen.2025.26327}
}
Kostenlos starten →